|
Market Closed -
Nasdaq
00:00:00 08/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 4.360 USD | +1.51% |
|
+1.16% | -62.58% |
| 08-14 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-14 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: ARS Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 799.9 | 526.1 | 1,025 | 1,152 | 433.6 | - | - |
| Change | - | -34.23% | 94.9% | 12.32% | -62.35% | - | - |
| Enterprise Value (EV) | 525.5 | 297.7 | 1,025 | 1,152 | 433.6 | 433.6 | 433.6 |
| Change | - | -43.35% | 244.4% | 12.32% | -62.35% | 0% | 0% |
| P/E | -9.8x | -9.61x | 132x | -6.7x | -2.36x | -5.16x | 87.2x |
| PBR | - | - | - | - | - | - | - |
| PEG | -2.03x | 0.3x | -1x | 0x | -0.37x | 0.1x | -1x |
| Capitalization / Revenue | 608x | 17,535x | 11.5x | 13.7x | 3.34x | 2.27x | 1.49x |
| EV / Revenue | 0x | 0.01x | 0x | 0x | 3.34x | 2.27x | 1.49x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -2.34x | -5.12x | 79.1x |
| EV / FCF | - | - | 0x | -0x | -2.26x | -7.84x | 8.66x |
| FCF Yield | - | - | 1.27% | -14.9% | -44.3% | -12.8% | 11.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.87 | -0.57 | 0.08 | -1.74 | -1.85 | -0.845 | 0.05 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.316 | 0.03 | 89.15 | 84.28 | 129.9 | 190.6 | 290.3 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -35.52 | -67.52 | -3.083 | -179.4 | -185.3 | -84.67 | 5.48 |
| Net income 1 | -34.68 | -54.36 | 7.998 | -171.3 | -184 | -85.02 | 9.032 |
| Net Debt | -274.4 | -228.4 | - | - | - | - | - |
| Reference price 2 | 8.530 | 5.480 | 10.550 | 11.650 | 4.360 | 4.360 | 4.360 |
| Nbr of stocks (in thousands) | 93,770 | 95,997 | 97,185 | 98,849 | 99,447 | - | - |
| Announcement Date | 23/03/23 | 21/03/24 | 20/03/25 | 09/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.36x | - | - | - | 434M | |
| 21.73x | 7.76x | 15.59x | 1.37% | 74.68B | |
| 30.5x | 8.78x | 27.34x | 0.04% | 58.7B | |
| 33.66x | 6.05x | 18.11x | 0.96% | 48.36B | |
| -20.81x | 215.3x | -22.29x | -.--% | 43.05B | |
| 33.24x | 3.23x | 13.97x | -.--% | 42.48B | |
| 48.26x | 5.5x | 30.21x | -.--% | 41.39B | |
| 27.77x | 7.89x | 20.51x | 0.41% | 31.29B | |
| -14.93x | 5.54x | -6.96x | -.--% | 23.93B | |
| -61.76x | 11.97x | -60.92x | -.--% | 22.22B | |
| Average | 9.53x | 30.22x | 3.95x | 0.31% | 38.65B | |
| Weighted average by Cap. | 17.32x | 30.22x | 9.46x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRY Stock
- Valuation ARS Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
